Denali Therapeutics Inc
NASDAQ:DNLI

Watchlist Manager
Denali Therapeutics Inc Logo
Denali Therapeutics Inc
NASDAQ:DNLI
Watchlist
Price: 20.78 USD -3.12% Market Closed
Market Cap: 3B USD
Have any thoughts about
Denali Therapeutics Inc?
Write Note

Denali Therapeutics Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Denali Therapeutics Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Denali Therapeutics Inc
NASDAQ:DNLI
PP&E Net
$113.2m
CAGR 3-Years
17%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
PP&E Net
$5.1B
CAGR 3-Years
0%
CAGR 5-Years
10%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
PP&E Net
$5.4B
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
14%
Amgen Inc
NASDAQ:AMGN
PP&E Net
$6.2B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
PP&E Net
$2.5B
CAGR 3-Years
23%
CAGR 5-Years
26%
CAGR 10-Years
13%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
PP&E Net
$4.4B
CAGR 3-Years
9%
CAGR 5-Years
10%
CAGR 10-Years
18%
No Stocks Found

Denali Therapeutics Inc
Glance View

Market Cap
3B USD
Industry
Biotechnology

In the heart of the biotech innovation hub that is California, Denali Therapeutics Inc. emerges as a promising beacon in the landscape of neurodegenerative disease treatment. Established by a team of pioneers in 2015, the company aims to combat the pressing challenge of diseases like Alzheimer's, Parkinson’s, and ALS. At the core of Denali’s mission is a sophisticated approach that intersects genetics, engineering, and clinical research. This biotech firm is not just about dreaming big; it operationalizes its vision through a science-driven methodology. Denali leverages its proprietary "Transport Vehicle" technology to enhance the delivery of therapeutic antibodies across the blood-brain barrier—a critical hurdle in treating neurological disorders. By addressing genetic underpinnings and homeostasis dysfunctions, Denali positions itself as a driver of transformative healthcare solutions. Denali's business model revolves around the development and commercialization of novel therapeutics. With a focus on high unmet needs, the company aligns its research objectives with revenue generation through strategic collaborations and partnerships. These alliances bolster Denali’s financial foundation, offering resources and expertise to hasten drug development and commercialization. Denali engages in research and licensing agreements that bring in upfront payments, milestone rewards, and future royalties. This approach not only diversifies its income streams but also mitigates risks associated with drug development intricacies. As Denali nurtures its pipeline, revenue opportunities expand, resting on the successful translation of groundbreaking science into tangible, market-ready solutions that offer hope to millions grappling with debilitating neurological conditions.

DNLI Intrinsic Value
16.81 USD
Overvaluation 19%
Intrinsic Value
Price

See Also

What is Denali Therapeutics Inc's PP&E Net?
PP&E Net
113.2m USD

Based on the financial report for Sep 30, 2024, Denali Therapeutics Inc's PP&E Net amounts to 113.2m USD.

What is Denali Therapeutics Inc's PP&E Net growth rate?
PP&E Net CAGR 5Y
7%

Over the last year, the PP&E Net growth was 51%. The average annual PP&E Net growth rates for Denali Therapeutics Inc have been 17% over the past three years , 7% over the past five years .

Back to Top